Showing results 1 to 9 of 9
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
2013 | 64 | |||
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial Proceeding/Conference:Journal of Clinical Oncology | 2014 | 46 | ||
2016 | 30 | |||
Modulation of angiogenic biomarkers in patients receiving high-dose TRC105 Proceeding/Conference:Journal of Clinical Oncology | 2012 | 35 | ||
7-Mar-2014 | 60 | |||
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105 Journal:Molecular Cancer Therapeutics | 2018 | 16 | ||
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors Journal:Invest New Drugs | 2014 | 54 | ||
2014 | 49 | |||
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance) Proceeding/Conference:Journal of Clinical Oncology | 2014 | 36 |